Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) | MicrobiomeTrials← Back to trialsNCT05733572
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2023-06-12Est. Completion: 2027-06-30
Enrollment target: 36 participants Locations- Catholic University, Policlinico A. Gemelli (Hospital), Rome, Italy
Other microbiome trials you might be interested in
Unruptured Intracranial AneurysmsPituitary Neuroendocrine TumorCraniopharyngiomaMeningiomaGerminomaRathke Cleft CystsChordomaOptic Pathway GliomaHypothalamic Neoplasms
The goal of this observational study is to learn about the treatment strategies for tumor in sellar region with unruptur…
Beijing, ChinaEst. completion Sep 1, 2028
Recurrent Glioma
Recurrent Malignant Glioma
This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in pat…
Los Angeles, United StatesEst. completion Nov 15, 2023